Hemminki, K., B. Müller-Myhsok, P. Lichtner, C. Engel, B. W. Chen, B. Burwinkel, A. Försti, C. Sutter, B. Wappenschmidt, H. Hellebrand, T. Illig, N. Arnold, D. Niederacher, B. Dworniczak, H. Deissler, K. Kast, D. Gadzicki, T. Meitinger, H. E. Wichmann, M. Kiechle, C. R. Bartram, R. K. Schmutzler and A. Meindl: Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. In: International Journal of Cancer 126, 12, 2858-2862 (2010).
Tchatchou, S., A. Riedel, S. Lyer, J. Schmutzhard, O. Strobel-Freidekind, S. Gronert-Sum, C. Mietag, M. D'Amato, B. Schlehe, K. Hemminki, C. Sutter, N. Ditsch, A. Blackburn, L. Z. Hill, D. J. Jerry, P. Bugert, B. H. Weber, D. Niederacher, N. Arnold, R. Varon-Mateeva, B. Wappenschmidt, R. K. Schmutzler, C. Engel, A. Meindl, C. R. Bartram, J. Mollenhauer and B. Burwinkel: Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity.. In: Human Mutations 31, 1, 60-66 (2010).
url: http://www.ncbi.nlm.nih.gov/pubmed/19830809
doi: 10.1002/humu.21134
Sadr-Nabavi, A., J. Ramser, J. Volkmann, J. Naehrig, F. Wiesmann, B. Betz, H. Hellebrand, S. Engert, S. Seitz, R. Kreutzfeld, T. Sasaki, N. Arnold, R. Schmutzler, M. Kiechle, D. Niederacher, N. Harbeck, E. Dahl and A. Meindl: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. In: International Journal of Cancer 124, 7, 1727-1735 (2009).
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.